CAP Peralada
- Address
- lock Available on a paid plan
CAP Peralada - Infectious Disease & Cardiovascular Research Center
CAP Peralada is a clinical research facility conducting pivotal trials in both infectious disease prevention and cardiovascular disease management. The center demonstrates expertise in vaccine immunogenicity studies and cardiovascular prevention trials, contributing to advancing therapeutic interventions across multiple patient populations.
- COVID-19 vaccine development and heterologous booster immunogenicity in adolescent populations
- Primary prevention of atherosclerotic cardiovascular disease using novel lipid-lowering therapies
- Safety and tolerability assessment of innovative biopharmaceutical interventions
The center's research portfolio includes multi-center non-inferiority studies evaluating SARS-CoV-2 infection prevention through next-generation vaccines in adolescents aged 12 to 18 years, as well as large-scale cardiovascular outcome trials. Their involvement in the VICTORION-1 PREVENT study demonstrates capability in conducting complex randomized, double-blind, placebo-controlled trials targeting major adverse cardiovascular events (MACE) reduction through inclisiran therapy in high-risk primary prevention patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CAP Peralada
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Inclisiran in Reducing Major Adverse Cardiovascular Events in High-Risk Primary Prevention of Atherosclerotic Cardiovascular Disease | Novartis Pharma AG | Phase III | Not Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.